Role of PD-1 Inhibitors in the Treatment of Esophagogastric Adenocarcinoma: Patient Selection and Reported Outcomes

Esophagogastric cancers are aggressive malignancies, with poor prognosis despite current standard-of-care therapies. PD-1 inhibitors are a newer class of antitumor agents with the potential to improve outcomes among appropriately selected patients. This review provides an overview of the key trials...

Descripción completa

Detalles Bibliográficos
Autores principales: Epistola, Raisa, Sperandio, Rubens, Wainberg, Zev, Iqbal, Syma, Chao, Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10032141/
https://www.ncbi.nlm.nih.gov/pubmed/36969544
http://dx.doi.org/10.2147/CMAR.S341468

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10032141/
https://www.ncbi.nlm.nih.gov/pubmed/36969544
http://dx.doi.org/10.2147/CMAR.S341468

Ejemplares similares